Sarepta Therapeutics has an accrual ratio of 0.79 for the year to September 2024. Statistically speaking, that's a real negative for future earnings. To wit, the company did not generate one whit of ...

Sarepta Therapeutics (Nasdaq: SRPT) has announced it will cease development of SRP-5051, an experimental drug for Duchenne ...

Sarepta Therapeutics is advancing SRP-9003 gene therapy for LGMD, with phase 3 study results expected in early 2025. Learn ...

An FDA expansion of Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) Elevidys has sparked a new surge in sales for the ...

JPMorgan sees a long-term buying opportunity after Sarepta (SRPT) shares were under pressure last week post earnings. Near-term, if one ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...

Sarepta Therapeutics (NASDAQ: SRPT) Q3 2024 Earnings Call Nov 06, 2024, 4:30 p.m. ET ...

Scientists who want a say in the future of their inventions are once again moving from academia to the C-suite ...

Sales of Elevidys are quickly gaining ground on Sarepta's exon-skipping trio, which need to be dosed chronically. In the ...

Gain insight on Rigel Pharmaceuticals, AbbVie and more in the latest Market Talks covering the Health Care sector.

Analyst Gil Blum of Needham maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), retaining the price target of ...

Investors consider Dyne Therapeutics' treatments for muscle diseases and strong cash position as a speculative Buy ...